Announcement of The Financial Report for The Year of 2020
2021.3.19
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 3 | Date of announcement | 2021/03/19 | Time of announcement | 18:04:17 |
| Subject | Announcement of The Financial Report for The Year of 2020 | ||||
| Date of events | 2021/03/19 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the financial reports submitted to the board of directors or approved by the board of directors:2021/03/19 2.Date of the financial reports approved by the audit committee:2021/03/19 3.Start and end dates of financial reports of the reporting period:2020/01/01~2020/03/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):4,221,836 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):2,607,052 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):957,379 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):1,201,525 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):978,677 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):924,178 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):3.72 11.Total assets end of the period (thousand NTD):9,360,809 12.Total liabilities end of the period (thousand NTD):3,282,741 13.Equity attributable to owners of parent end of the period (thousand NTD):5,449,766 14.Any other matters that need to be specified: Basic earnings per share presented NTD 3.72 on financial report for year 2020, which is higher than that as NTD 3.38 as announced preliminary financial result on 2021.1.18. The reason for variance was due to more equity income from invested company to recognize sales milestone royalty in year 2020. |
||||